Methods for assessing mucosal healing in crohn's disease patients
AssigneePrometheus Biosciences, Inc.
InventorsAnjali JAIN, Venkateswarlu KONDRAGUNTA, Michael Hale
Life of this patent
Estimating the term…
Abstract
of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.
Claims27
A method for assessing mucosal healing in a patient with Crohn's Disease (CD), the method comprising:
- providing a serum sample from a patient;
- detecting in the serum sample an expression level of each of the following biomarkers:
- Ang1, Ang2, CEACAM1, VCAM1, TGFα, CRP, SAA1, MMP-1, MMP-2, MMP-3, MMP-9, EMMPRIN, and IL-7;
- and
- applying a mathematical algorithm to the expression levels of the biomarkers, thereby producing a Mucosal Healing Index (MHI) score for the patient.
(canceled)
6-8. (canceled)
(canceled)
(canceled)
(canceled)
18-23. (canceled)
A method for assessing mucosal healing in a patient with CD, the method comprising:
- (a) detecting the expression of the following biomarkers in a serum sample from the patient:
- Ang1;
- Ang2;
- CEACAM1;
- VCAM1;
- TGFα;
- CRP;
- SAA1;
- MMP-1;
- MMP-2;
- MMP-3;
- MMP-9;
- EMMPRIN;
- and IL-7;
- and
- (b) applying a mathematical algorithm to the expression of the biomarkers in step (a) to produce an MHI for the patient,
- wherein the MHI is a scale of 0-100,
- wherein the patient is in remission or has mild endoscopic disease when the MHI is between 0-40, and
- wherein the patient has endoscopically active disease when the MHI is between 50-100.
34-55. (canceled)
Dependencies are inferred from the claim text.